Peter Høngaard Andersen

Dr. Andersen has held various leadership positions at global pharma companies, including Lundbeck A/S and Novo Nordisk in R&D, IP, litigation, public affairs, strategic development, business development and mergers and acquisitions. In his career, he has co-founded a number of biotech companies including Acadia Pharmaceuticals, Zealand Pharmaceuticals, Glycom and Epitherapeutics.

Most recently, Dr. Andersen has acted as an Adjunct Professor at the Copenhagen Business School in Health Care Innovation, and was Founder and Managing Director of Innovation Fund Denmark between 2014 and 2019 formed from a merger of three independent funds.

He received his Doctorate in Medicine from the University of Copenhagen Medical School. Dr. Andersen was Chairman of Forbion portfolio company Prexton Therapeutics, before it was successfully sold to Lundbeck A/S for up to $1Bn.